Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|February 9, 2013
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancerNeil E Bhola, Justin M Balko, Teresa C Dugger, et al.
Cancer Research|August 23, 2013
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancerJustin M Balko, Luis J Schwarz, Neil E Bhola, et al.
JCI Insight|October 8, 2021
Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switchJ William Tierney, Brian C Evans, Joyce Cheung-Flynn, et al.
Cancer Research|September 19, 2018
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast CancersDavid L Elion, Max E Jacobson, Donna J Hicks, et al.
Breast Cancer Research : BCR|July 2, 2017
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasisMeghan Morrison Joly, Michelle M Williams, Donna J Hicks, et al.
Cancer Research|April 13, 2011
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesisRebecca S Cook, Joan T Garrett, Violeta Sánchez, et al.
Molecular Cancer Research : MCR|January 1, 2017
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL BlockadeMichelle M Williams, Linus Lee, Donna J Hicks, et al.
Iscience|October 20, 2018
p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell AdhesionGabriela L Santos Guasch, J Scott Beeler, Clayton B Marshall, et al.
Oncoimmunology|June 7, 2018
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2Na Luo, Luigi Formisano, Paula I Gonzalez-Ericsson, et al.
Cancer Research|May 20, 2016
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast CancersMeghan Morrison Joly, Donna J Hicks, Bayley Jones, et al.
Pageof 9